HYA Advisors Inc lowered its stake in shares of Pfizer Inc. (NYSE:PFE) by 6.3% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 6,482 shares of the biopharmaceutical company’s stock after selling 437 shares during the period. HYA Advisors Inc’s holdings in Pfizer were worth $254,000 as of its most recent SEC filing.
Several other institutional investors have also added to or reduced their stakes in PFE. Benjamin Edwards Inc. increased its holdings in shares of Pfizer by 36.5% during the 1st quarter. Benjamin Edwards Inc. now owns 999 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 267 shares during the period. Alpha DNA Investment Management LLC boosted its position in Pfizer by 52.2% in the first quarter. Alpha DNA Investment Management LLC now owns 1,090 shares of the biopharmaceutical company’s stock valued at $39,000 after buying an additional 374 shares in the last quarter. Lake Point Wealth Management bought a new position in shares of Pfizer in the second quarter worth about $49,000. Harvest Fund Management Co. Ltd raised its stake in shares of Pfizer by 25,460.0% in the second quarter. Harvest Fund Management Co. Ltd now owns 1,278 shares of the biopharmaceutical company’s stock worth $50,000 after acquiring an additional 1,273 shares during the last quarter. Finally, KB Financial Partners LLC bought a new stake in shares of Pfizer during the first quarter worth approximately $62,000. Institutional investors and hedge funds own 64.93% of the company’s stock.
PFE has been the subject of several research analyst reports. Truist initiated coverage on shares of Pfizer in a report on Tuesday, July 27th. They issued a “buy” rating and a $43.00 price target for the company. Berenberg Bank reiterated a “neutral” rating and issued a $43.00 price target on shares of Pfizer in a report on Tuesday, June 15th. Mizuho upped their price target on shares of Pfizer from $42.00 to $43.00 and gave the company a “neutral” rating in a report on Friday, July 30th. Morgan Stanley increased their target price on shares of Pfizer from $42.00 to $45.00 and gave the stock an “equal weight” rating in a report on Thursday, July 29th. Finally, The Goldman Sachs Group set a $48.00 target price on shares of Pfizer in a report on Thursday, July 29th. Eleven research analysts have rated the stock with a hold rating and two have issued a buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus target price of $42.85.
Pfizer (NYSE:PFE) last announced its quarterly earnings data on Wednesday, July 28th. The biopharmaceutical company reported $1.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.97 by $0.10. The firm had revenue of $18.98 billion for the quarter, compared to the consensus estimate of $17.54 billion. Pfizer had a net margin of 23.06% and a return on equity of 26.49%. During the same period in the prior year, the company posted $0.78 earnings per share. As a group, equities research analysts forecast that Pfizer Inc. will post 4.12 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, December 6th. Shareholders of record on Friday, November 5th will be paid a dividend of $0.39 per share. The ex-dividend date of this dividend is Thursday, November 4th. This represents a $1.56 dividend on an annualized basis and a yield of 3.64%. Pfizer’s payout ratio is 70.27%.
In related news, SVP Jennifer B. Damico sold 1,661 shares of Pfizer stock in a transaction that occurred on Friday, August 13th. The shares were sold at an average price of $48.30, for a total transaction of $80,226.30. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, SVP Jennifer B. Damico sold 2,500 shares of the firm’s stock in a transaction that occurred on Friday, July 30th. The stock was sold at an average price of $42.86, for a total transaction of $107,150.00. Following the transaction, the senior vice president now owns 11,430 shares of the company’s stock, valued at approximately $489,889.80. The disclosure for this sale can be found here. Corporate insiders own 0.05% of the company’s stock.
Pfizer Inc is a research-based global biopharmaceutical company. It engages in the discovery, development, manufacture, marketing, sales and distribution of biopharmaceutical products worldwide. The firm work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases.
Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.